BR0208382A - Nicotine-containing oral dosage form - Google Patents

Nicotine-containing oral dosage form

Info

Publication number
BR0208382A
BR0208382A BR0208382-5A BR0208382A BR0208382A BR 0208382 A BR0208382 A BR 0208382A BR 0208382 A BR0208382 A BR 0208382A BR 0208382 A BR0208382 A BR 0208382A
Authority
BR
Brazil
Prior art keywords
nicotine
dosage form
oral dosage
containing oral
oral
Prior art date
Application number
BR0208382-5A
Other languages
Portuguese (pt)
Inventor
John Liu
Stanley J Lech
Stuart Platcow
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0208382A publication Critical patent/BR0208382A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMA DE DOSAGEM ORAL CONTENDO NICOTINA". A presente invenção refere-se a formas de dosagem oral sólida de matriz vítrea úteis para a administração oral transmucosal de um ativo de nicotina."ORAL DOSAGE FORM CONTAINING NICOTINE". The present invention relates to solid oral glass matrix dosage forms useful for transmucosal oral administration of a nicotine active.

BR0208382-5A 2001-03-26 2002-03-22 Nicotine-containing oral dosage form BR0208382A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27860601P 2001-03-26 2001-03-26
PCT/US2002/008914 WO2002076211A1 (en) 2001-03-26 2002-03-22 Nicotine-containing oral dosage form

Publications (1)

Publication Number Publication Date
BR0208382A true BR0208382A (en) 2004-06-15

Family

ID=23065632

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208382-5A BR0208382A (en) 2001-03-26 2002-03-22 Nicotine-containing oral dosage form

Country Status (11)

Country Link
EP (1) EP1372392A4 (en)
JP (1) JP2004525928A (en)
CN (2) CN1553771A (en)
AR (1) AR033444A1 (en)
AU (1) AU2002252470B2 (en)
BR (1) BR0208382A (en)
CA (1) CA2440713A1 (en)
MX (1) MXPA03008762A (en)
NZ (1) NZ528167A (en)
PL (1) PL364621A1 (en)
WO (1) WO2002076211A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
AR045076A1 (en) * 2003-07-24 2005-10-12 Smithkline Beecham Plc COMPOSITION OF FILM THAT DISSOLVES ORALALLY, MULTICOMPONENT FILM THAT DISSOLVES ORALALLY, USE OF THE FILM COMPOSITION AND THE FILM THAT ORALLY DISSOLVES TO PREPARE A MEDICINAL PRODUCT, FORM OF ORAL DOSAGE AND PROCEDURE FOR PREPARATION OF COMPOSITION
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
WO2005046363A2 (en) 2003-11-07 2005-05-26 U.S. Smokeless Tobacco Company Tobacco compositions
JP4964773B2 (en) * 2004-08-11 2012-07-04 クラフト・フーヅ・グローバル・ブランズ・エルエルシー Sensory initiator composition and delivery system thereof
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2008069921A2 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
KR101122469B1 (en) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 Methods and compositions for reduction of side effects of therapeutic treatments
DE102008012015A1 (en) 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Improved isomalt-containing compresses and processes for their preparation
KR20130008535A (en) * 2010-02-18 2013-01-22 자틴 바산트 타카르 Nicotine-containing soft gelatin pastilles
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
UA112974C2 (en) * 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид NICOTINE COMPOSITION (OPTIONS)
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst Compositions and methods for treatment of symptoms in parkinson's disease patients
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
TW201507726A (en) * 2013-05-10 2015-03-01 Glaxosmithkline Llc Nicotine lozenge formulation
CN104132895B (en) * 2014-07-08 2017-08-25 国家烟草质量监督检验中心 The buffer system of total alkaloid tobacco and tobacco product is determined suitable for continuous flow method
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
SE541358C2 (en) * 2017-05-30 2019-08-13 Enorama Pharma Ab Nicotine-containing chewing gum compositions
JP7420797B2 (en) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド Drug delivery methods and systems
CA3167882A1 (en) * 2020-01-15 2021-07-22 Mcneil Ab Lozenge
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE19536394A1 (en) * 1995-09-29 1997-04-03 Basf Ag Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt
DE19639342C2 (en) * 1996-09-25 1998-07-16 Suedzucker Ag Chewing gum containing a sweetener
US6322806B1 (en) * 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center

Also Published As

Publication number Publication date
CA2440713A1 (en) 2002-10-03
WO2002076211A1 (en) 2002-10-03
EP1372392A4 (en) 2004-06-23
CN101301275A (en) 2008-11-12
AU2002252470B2 (en) 2008-05-22
EP1372392A1 (en) 2004-01-02
JP2004525928A (en) 2004-08-26
NZ528167A (en) 2005-04-29
PL364621A1 (en) 2004-12-13
CN1553771A (en) 2004-12-08
AR033444A1 (en) 2003-12-17
MXPA03008762A (en) 2004-02-18

Similar Documents

Publication Publication Date Title
BR0208382A (en) Nicotine-containing oral dosage form
MXPA05002942A (en) Modified release oral dosage form.
HUP0203176A2 (en) Solid, oral pharmaceutical composition containing simethicone
HUP0302086A2 (en) Oral pharmaceutical composition with a delayed action and process for its preparation
HK1076605A1 (en) Formulations
DE60205870D1 (en) ORAL PHARMACEUTICAL COMPOSITION OF CEFPODOXIM PROXETIL
NO993520D0 (en) Dosage forms and methods for improving erectile dysfunction
EA200401019A1 (en) DOSED MEDICAL FORM FOR ORAL APPLICATION CONTAINING PDE 4 INHIBITOR AS AN ACTIVE SUBSTANCE AND POLYVINYLPYRROLIDONE AS AN AUXILIARY
HUP0101237A1 (en) Sustained release preparations
HUP0302131A2 (en) Pharmaceutical tramadol salts, pharmaceutical compositions containing them
NO324227B1 (en) Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases
TR200100172T2 (en) Biologically strengthened formulations containing eprosartan in oral solid dosage form
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
MX2007015480A (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption.
SE0103211D0 (en) New formulations and use thereof
HUP0104647A2 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
ATE339224T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING HONEY FOR WOUND TREATMENT
SE0102440D0 (en) New compound
DE60102590T2 (en) PHARMACEUTICAL FORMS FOR THE TREATMENT OF ORAL MYCOSES
DE69804865D1 (en) SOLID MILTEFOSIN CONTAINING MEDICINES FOR ORAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS
FI20000780A (en) Oral dosage form for controlled release of the drug
EA200501697A1 (en) DOSABLE FORM CONTAINING PANTOPRAZOL AS AN ACTIVE INGREDIENT
BR0114395A (en) Pharmaceutical composition for oral supply administration
ATE338567T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING ACTIVE INGREDIENTS SUITABLE FOR UNAUTHORIZED ADMINISTRATION
HUP0302880A2 (en) Pharmaceutical compositions containing a crystal modification of a cyclic depsipeptide having improved activity

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A(S) 9A ANUIDADE(S)

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.